FDA adverse event collection workshop
FDA's Center for Drug Evaluation and Research will hold a public workshop Jan. 29 to solicit information on research approaches to assessing the public health benefit of collecting and reporting all adverse events throughout the product's marketed life cycle. The workshop objectives, co-sponsored by the Center for Biologics, are to initiate dialogue and information-sharing among stakeholders affected by postmarketing AE collection, reporting and evaluation; share current FDA practices and what questions should be addressed by requests for proposals; and obtain input on the questions and methods that will be used to conduct research. The input will be used to publish a formal request for information, followed by an RFP...
You may also be interested in...
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.
EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care
Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.